Replies to post #1052 on Idenix Pharmaceuticals (IDIX)

[go seek]

Thank you Jon... nice to see a positive trend (for a change : )

TYZEKA is significantly better than Hepsera. An analysis of clinical data shows this.

1Q07 Hepsera sales were $71.3M ($285M annualized), +35% year-over-year, +8% quarter-over-quarter.
http://www.investorshub.com/boards/read_msg.asp?message_id=18908687

Idenix has a quality HBV product... and this product may be enhanced //..\\ by valtorcitabine and nucleotides
http://www.investorshub.com/boards/read_msg.asp?message_id=18910784